Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
4
×
clinical trials
life sciences
national blog main
rna interference
4
×
drugs
fda
patisiran
akcea therapeutics
aminolevulinic acid
givosiran
hereditary transthyretin amyloidosis
inotersen
national top stories
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
vyndaqel
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
andrew fire
barry greene
biotech
boston university
craig mello
dan ollendorf
john berk
john maraganore
mary o'donnell
nobel prize
What
alnylam
medicine
4
×
drug
fda
pharmaceuticals
rna
rnai
ago
interference
ok
second
seek
speedy
afternoon
alnylam’s
approval
approve
approved
awaits
biological
cleared
crossed
data
decades
decision
discovered
far
fingers
friday
gets
historic
history
indicated
landmark
making
market
nasdaq
new
nod
onpattro
Language
Current search:
xconomy.com
×
medicine
×
" boston top stories "
×
" rna interference "
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision